HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.

AbstractBACKGROUND:
We hypothesized that tacrolimus, an inhibitor of the calcineurin pathway, would enhance the in vivo activity of posaconazole against Rhizopus oryzae, the Mucorales species most commonly associated with mucormycosis.
METHODS:
We examined patterns of growth inhibition and fungicidal activity of posaconazole and tacrolimus, alone and in combination, against R. oryzae in vitro, using multiple methods (ie, hyphal metabolic and fluorescent vital dye reduction assays and measurement of chitin concentrations), and in vivo, using 2 mucormycosis models: an invertebrate model (Drosophila) and a nonlethal murine model of cutaneous mucormycosis.
RESULTS:
Combinations of posaconazole and tacrolimus were synergistic in checkerboard assays for 4 clinical isolates of R. oryzae (48-hour fractional inhibitory concentration index, 0.187-0.281). Pharmacodynamic analysis of the combination revealed that the 90% effective concentration threshold of posaconazole activity against R. oryzae could be achieved with 2-fold lower drug concentrations (0.5-1 mg/L) when administered with tacrolimus (0.007-2 mg/L). In vivo, combination therapy was associated with improved survival in the fly model of mucormycosis (65% vs 57% posaconazole alone) and with significant reductions in cutaneous lesions and R. oryzae fungal burden, compared with animals that received posaconazole monotherapy, in the cutaneous model of mucormycosis.
CONCLUSIONS:
Combination posaconazole-tacrolimus therapy displays synergism in vitro and improved antifungal efficacy in vivo in 2 phylogenetically distinct models of mucormycosis.
AuthorsRussell E Lewis, Ronen Ben-Ami, Leyla Best, Nathaniel Albert, Thomas J Walsh, Dimitrios P Kontoyiannis
JournalThe Journal of infectious diseases (J Infect Dis) Vol. 207 Issue 5 Pg. 834-41 (Mar 01 2013) ISSN: 1537-6613 [Electronic] United States
PMID23242544 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Antifungal Agents
  • Triazoles
  • posaconazole
  • Tacrolimus
Topics
  • Animals
  • Antifungal Agents (administration & dosage, pharmacology)
  • Disease Models, Animal
  • Drosophila (microbiology)
  • Drug Synergism
  • Drug Therapy, Combination (methods)
  • Female
  • Mice
  • Mice, Inbred BALB C
  • Microbial Sensitivity Tests
  • Mucormycosis (drug therapy)
  • Rhizopus (drug effects)
  • Tacrolimus (administration & dosage, pharmacology)
  • Treatment Outcome
  • Triazoles (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: